Tag: Mydecine - Page 2 - Psychedelic Alpha

Read more about the article Mydecine Signs LOI with The Newly Institute to Provide Psychedelic-Assisted Psychotherapy to Patients under Health Canada’s Special Access Program

Mydecine Signs LOI with The Newly Institute to Provide Psychedelic-Assisted Psychotherapy to Patients under Health Canada’s Special Access Program

Post published:January 18, 2022
Post category:Press Release

Read more about the article Mydecine to Launch Special Access Support and Supply Program in Canada Expanding Access to Psychedelic-Assisted Psychotherapy For Patients

Mydecine to Launch Special Access Support and Supply Program in Canada Expanding Access to Psychedelic-Assisted Psychotherapy For Patients

Post published:January 13, 2022
Post category:Press Release

Read more about the article Mydecine Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development Enabling Quick Screening of Billions of Compounds

Mydecine Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development Enabling Quick Screening of Billions of Compounds

Post published:January 10, 2022
Post category:Press Release

Mydecine Innovations Group Engages JBN Partners, LLC for Marketing Services

Post published:January 7, 2022
Post category:Press Release

Read more about the article Mydecine Signs LOI with Maya to Co-Develop a Novel Prescription Digital Therapeutic Platform Aiming to Further Increase Safety, Efficacy, and Accessibility of Psychedelic-Assisted Treatments

Mydecine Signs LOI with Maya to Co-Develop a Novel Prescription Digital Therapeutic Platform Aiming to Further Increase Safety, Efficacy, and Accessibility of Psychedelic-Assisted Treatments

Post published:December 22, 2021
Post category:Press Release

Read more about the article Mydecine Secures Financing and Provides Company Update on Clinical Trials, Drug Development and Technology Initiatives

Mydecine Secures Financing and Provides Company Update on Clinical Trials, Drug Development and Technology Initiatives

Post published:December 9, 2021
Post category:Press Release

Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs

Post published:December 6, 2021
Post category:Press Release

Read more about the article Mydecine’s Chief Medical Officer, Dr. Rakesh Jetly, to Participate at Horizons’ Veterans & Families Forum on November 10, 2021

Mydecine’s Chief Medical Officer, Dr. Rakesh Jetly, to Participate at Horizons’ Veterans & Families Forum on November 10, 2021

Post published:November 10, 2021
Post category:Press Release

Read more about the article Mydecine Files Full Patent Application Covering New Formulations that Bring Nanoemulsion Technology to Traditional Medicine Ingredients

Mydecine Files Full Patent Application Covering New Formulations that Bring Nanoemulsion Technology to Traditional Medicine Ingredients

Post published:November 3, 2021
Post category:Press Release

Mydecine Reports Successful Synthesis of Novel Tryptamine Improving the Pharmaceutical Properties of Psilocin

Post published:October 27, 2021
Post category:Press Release

Weekly Bulletin

Your weekly recap of news and analysis from the psychedelic sector.

Research Review

A monthly review of the most important psychedelics research.

News & Interviews

The latest news from across the psychedelics space.

Psychedelics Patent Trackers

We track the latest patents and filings related to psilocybin, MDMA and DMT.

Psychedelic Legalization & Decriminalization Tracker

Mapping psychedelic drug policy reform across the United States

Psychedelics Drug Development Tracker

From drug discovery to regulatory approval, we map drug development in psychedelics.

Stocks & Companies Directory

A directory of all the major psychedelics stocks, companies and ETFs.

Sector Landscape Map

Explore the Psychedelic Sector Landscape visually using our new tool.

Stock Watchlist

A one-stop overview of psychedelics stocks financial performance.

Mydecine Signs LOI with The Newly Institute to Provide Psychedelic-Assisted Psychotherapy to Patients under Health Canada’s Special Access Program

Mydecine to Launch Special Access Support and Supply Program in Canada Expanding Access to Psychedelic-Assisted Psychotherapy For Patients

Mydecine Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development Enabling Quick Screening of Billions of Compounds

Mydecine Innovations Group Engages JBN Partners, LLC for Marketing Services

Mydecine Signs LOI with Maya to Co-Develop a Novel Prescription Digital Therapeutic Platform Aiming to Further Increase Safety, Efficacy, and Accessibility of Psychedelic-Assisted Treatments

Mydecine Secures Financing and Provides Company Update on Clinical Trials, Drug Development and Technology Initiatives

Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs

Mydecine’s Chief Medical Officer, Dr. Rakesh Jetly, to Participate at Horizons’ Veterans & Families Forum on November 10, 2021

Mydecine Files Full Patent Application Covering New Formulations that Bring Nanoemulsion Technology to Traditional Medicine Ingredients

Mydecine Reports Successful Synthesis of Novel Tryptamine Improving the Pharmaceutical Properties of Psilocin

Psychedelic Alpha

Quick Links

Newsletter

Join Our Newsletter

Psychedelic sector insights, interviews and analysis delivered to your inbox.

No thanks, continue to site.